Puneet Souda
Stock Analyst at Leerink Partners
(1.59)
# 3,431
Out of 5,044 analysts
218
Total ratings
49.15%
Success rate
-0.83%
Average return
Main Sectors:
Stocks Rated by Puneet Souda
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TMO Thermo Fisher Scientific | Maintains: Outperform | $545 → $580 | $557.63 | +4.01% | 20 | Oct 22, 2025 | |
| HOLX Hologic | Maintains: Market Perform | $70 → $78 | $74.01 | +5.39% | 8 | Oct 21, 2025 | |
| GH Guardant Health | Maintains: Outperform | $70 → $75 | $69.58 | +7.79% | 6 | Sep 25, 2025 | |
| CYRX Cryoport | Upgrades: Outperform | $16 | $9.04 | +76.99% | 7 | Aug 6, 2025 | |
| MASS 908 Devices | Upgrades: Outperform | $12 | $7.99 | +50.19% | 7 | Aug 5, 2025 | |
| QTRX Quanterix | Downgrades: Market Perform | $12 → $8 | $5.48 | +45.99% | 12 | Apr 30, 2025 | |
| NEO NeoGenomics | Downgrades: Market Perform | $25 → $9 | $9.92 | -9.27% | 10 | Apr 30, 2025 | |
| MYGN Myriad Genetics | Downgrades: Market Perform | $30 → $21 | $8.13 | +158.30% | 7 | Dec 9, 2024 | |
| VCYT Veracyte | Maintains: Outperform | $35 → $40 | $35.60 | +12.36% | 14 | Oct 17, 2024 | |
| NTRA Natera | Maintains: Outperform | $140 → $150 | $189.57 | -20.87% | 7 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $325 → $375 | $345.95 | +8.40% | 15 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $35 | $24.15 | +44.93% | 11 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $170 → $145 | $145.85 | -0.58% | 19 | May 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $300 | $216.90 | +38.31% | 1 | May 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $249 → $250 | $97.80 | +155.62% | 19 | Feb 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $125 → $110 | $63.94 | +72.04% | 6 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $75 | $63.30 | +18.48% | 16 | Jan 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $230 → $200 | $151.57 | +31.95% | 7 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $18 | $5.63 | +219.72% | 6 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $6 | $1.55 | +287.10% | 1 | Nov 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $45 → $30 | $33.57 | -10.63% | 6 | Nov 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $85 → $87 | $38.72 | +124.69% | 13 | May 5, 2022 |
Thermo Fisher Scientific
Oct 22, 2025
Maintains: Outperform
Price Target: $545 → $580
Current: $557.63
Upside: +4.01%
Hologic
Oct 21, 2025
Maintains: Market Perform
Price Target: $70 → $78
Current: $74.01
Upside: +5.39%
Guardant Health
Sep 25, 2025
Maintains: Outperform
Price Target: $70 → $75
Current: $69.58
Upside: +7.79%
Cryoport
Aug 6, 2025
Upgrades: Outperform
Price Target: $16
Current: $9.04
Upside: +76.99%
908 Devices
Aug 5, 2025
Upgrades: Outperform
Price Target: $12
Current: $7.99
Upside: +50.19%
Quanterix
Apr 30, 2025
Downgrades: Market Perform
Price Target: $12 → $8
Current: $5.48
Upside: +45.99%
NeoGenomics
Apr 30, 2025
Downgrades: Market Perform
Price Target: $25 → $9
Current: $9.92
Upside: -9.27%
Myriad Genetics
Dec 9, 2024
Downgrades: Market Perform
Price Target: $30 → $21
Current: $8.13
Upside: +158.30%
Veracyte
Oct 17, 2024
Maintains: Outperform
Price Target: $35 → $40
Current: $35.60
Upside: +12.36%
Natera
Oct 17, 2024
Maintains: Outperform
Price Target: $140 → $150
Current: $189.57
Upside: -20.87%
Aug 1, 2024
Upgrades: Outperform
Price Target: $325 → $375
Current: $345.95
Upside: +8.40%
Jun 5, 2023
Maintains: Outperform
Price Target: $50 → $35
Current: $24.15
Upside: +44.93%
May 24, 2023
Maintains: Outperform
Price Target: $170 → $145
Current: $145.85
Upside: -0.58%
May 1, 2023
Initiates: Outperform
Price Target: $300
Current: $216.90
Upside: +38.31%
Feb 8, 2023
Maintains: Outperform
Price Target: $249 → $250
Current: $97.80
Upside: +155.62%
Feb 3, 2023
Maintains: Outperform
Price Target: $125 → $110
Current: $63.94
Upside: +72.04%
Jan 12, 2023
Maintains: Outperform
Price Target: $70 → $75
Current: $63.30
Upside: +18.48%
Jan 6, 2023
Maintains: Outperform
Price Target: $230 → $200
Current: $151.57
Upside: +31.95%
Jan 6, 2023
Maintains: Outperform
Price Target: $20 → $18
Current: $5.63
Upside: +219.72%
Nov 29, 2022
Initiates: Outperform
Price Target: $6
Current: $1.55
Upside: +287.10%
Nov 21, 2022
Maintains: Market Perform
Price Target: $45 → $30
Current: $33.57
Upside: -10.63%
May 5, 2022
Maintains: Outperform
Price Target: $85 → $87
Current: $38.72
Upside: +124.69%